5-fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1789-1793

  Rougier, Ph ^a,g   Paillot, B ^b   LaPlanche, A ^a   Morvan, F ^c   Seitz, J F ^d   Rekacewicz, C ^a   Laplaige, P ^g   Jacob, J ^e   Grandjouan, S ^f   Tigaud, J M ^a   Fabri, M C ^a   Luboinski, M ^a   Ducreux, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Centre Hospitalier Becquerel   (France)

^c HÔPITAL DU BOCAGE   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e Institut F Baclesse   (France)

^f Hop Cochin ^*  (France)

^g NONE

Author keywords

Glue; Tape

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL;

ADULT; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTINUOUS INFUSION; FEMALE; FOOT DISEASE; GRANULOCYTOPENIA; HAND DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0031431131     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00175-5     Document Type: Article

References (20)

1. Hryniuk WM. The importance of dose intensity in outcome of chemotherapy. In DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia PA, JB Lippincott Company, 1988, 121-142.
2. Matsushima Y, Kanzawa F, Hoshi A, et al. Time schedule dependency of the inhibiting activity of various anticancer drugs in clonogentic assay. Cancer Chemother Pharmacol 1985, 14, 104-107.
3. Seifert P, Baker LH, Reed ML, et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975, 36, 123-128.
4. Lokich JJ, Ahigren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989, 7, 425-432.
5. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995, 13, 1303-1311.
6. Hansen R, Ryan L, Anderson T, et al. A phase III trial of bolus versus protracted infusion 5FU +/-cisplatin in metastatic colorectal cancer. An Eastern Cooperative Oncology Group study (EST 2286). Proc Am Soc Clin Oncol 1992, 11, 171.
7. Isacson S. 5-fluorouracil and folinic acid in the treatment of colorectal carcinoma: a randomized trial of two different schedules of administration. Second International Conference on Gastro-Intestinal Cancer (1989) abstract.
8. Weinerman B, Shah A, Fields A, et al. Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol 1992, 15, 518-523.
9. Rougier P, Ammargellat H, Ghosn M, et al. Phase II trial of 7-day continuous 5-flourouracil infusion in the treatment of advanced colorectal carcinoma. Oncology 1992, 49, 35-39.
10. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
11. Kaplan EL, Meier P. Non parametric estimations from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
12. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chron Dis 1978, 31, 557-560.
13. Peto R, Pike MC, Armitrage P, et al. Design and analysis of randomised clinical trials requiring prolonged observations of each patient. II Analysis and examples. Br J Cancer 1977, 35, 1-39.
14. Cox DR. Regression models and life-tables. J R Stat Soc 1972, B34, 187-220.
15. Sobrero A, Aschele C, Guglielmi A, et al. High activity and low toxicity of alternating bolus and continuous infusion 5-fluorouracil with schedule-oriented biochemical modulation in advanced colon cancer patients. Proc Am Soc Clin Oncol 1994, 13, 200.
16. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7, 1407-1418.
17. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7, 1407-1418.
18. Conroy T, Adenis A, Brucker P, et al. A prospective randomized trial of protracted infusional 5-FU with allopurinol versus bolus 5-FU with allopurinol versus 5-FU and high dose leucovorin in metastatic colorectal cancers. Proc Am Soc Clin Oncol 1992, 11, 162.
19. Tempero M, Berg A, Block M, et al. A phase II trial of protracted therapy with 5-fluorouracil and leucovorin in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1993, 12, 201.
20. Levi FA, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (Leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994, 86, 1608-1617.